JP5027387B2 - ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物 - Google Patents

ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物 Download PDF

Info

Publication number
JP5027387B2
JP5027387B2 JP2004518221A JP2004518221A JP5027387B2 JP 5027387 B2 JP5027387 B2 JP 5027387B2 JP 2004518221 A JP2004518221 A JP 2004518221A JP 2004518221 A JP2004518221 A JP 2004518221A JP 5027387 B2 JP5027387 B2 JP 5027387B2
Authority
JP
Japan
Prior art keywords
cells
hyaluronan
cancer
oligomers
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004518221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532373A (ja
JP2005532373A5 (enExample
Inventor
トゥール、ブライアン・ピー
シブナス、ガータク
スニティ、ミズラ
Original Assignee
タフツ・ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タフツ・ユニバーシティ filed Critical タフツ・ユニバーシティ
Publication of JP2005532373A publication Critical patent/JP2005532373A/ja
Publication of JP2005532373A5 publication Critical patent/JP2005532373A5/ja
Application granted granted Critical
Publication of JP5027387B2 publication Critical patent/JP5027387B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2004518221A 2002-07-01 2003-07-01 ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物 Expired - Fee Related JP5027387B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39290502P 2002-07-01 2002-07-01
US60/392,905 2002-07-01
US45376103P 2003-03-11 2003-03-11
US60/453,761 2003-03-11
PCT/US2003/020918 WO2004003545A1 (en) 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010013291A Division JP2010116410A (ja) 2002-07-01 2010-01-25 ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物

Publications (3)

Publication Number Publication Date
JP2005532373A JP2005532373A (ja) 2005-10-27
JP2005532373A5 JP2005532373A5 (enExample) 2010-03-18
JP5027387B2 true JP5027387B2 (ja) 2012-09-19

Family

ID=30003285

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004518221A Expired - Fee Related JP5027387B2 (ja) 2002-07-01 2003-07-01 ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物
JP2010013291A Pending JP2010116410A (ja) 2002-07-01 2010-01-25 ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010013291A Pending JP2010116410A (ja) 2002-07-01 2010-01-25 ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物

Country Status (6)

Country Link
US (2) US8093217B2 (enExample)
EP (2) EP1532434A4 (enExample)
JP (2) JP5027387B2 (enExample)
AU (1) AU2003280471B2 (enExample)
CA (1) CA2513143A1 (enExample)
WO (1) WO2004003545A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513143A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
AU2005287397A1 (en) * 2004-06-30 2006-03-30 Paul L. Deangelis Methods of selectively treating diseases with specific glycosaminoglycan polymers
CA2609467A1 (en) * 2005-05-26 2006-11-30 The Johns Hopkins University Compositions and methods for the treatment or prevention of chemoresistant neoplasia
EP2079846A4 (en) * 2006-10-03 2013-08-07 Univ Oklahoma TARGETED GLYCOSAMINOGLYCAN POLYMERS BY POLYMER GRAFTING AND MANUFACTURING AND USE METHOD THEREFOR
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
EP2097092A4 (en) * 2006-11-21 2010-04-07 MODULATION OF RHAMM (CD168) FOR THE SELECTIVE DEVELOPMENT OF ADIPOSIS TISSUE
US20100062000A1 (en) * 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
EP2307571A4 (en) * 2008-06-26 2012-03-07 Univ South Florida PROOF AND SENSITIZATION PROCEDURE FOR THE PLATINUM RESISTANCE OF CANCER DISORDERS
CA2703532C (en) * 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
RU2015123315A (ru) 2012-11-25 2017-01-10 Зе Реджентс Оф Зе Юниверсити Оф Калифорния Пептиды, стимулирующие подкожный адипогенез
KR20160099081A (ko) * 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
EP3271383A4 (en) 2015-03-20 2019-06-12 London Health Sciences Centre Research Inc. GASED PEPTIDES AND USES THEREOF
CN109715653A (zh) 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2850376B2 (ja) * 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5976874A (en) * 1996-08-16 1999-11-02 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
US6420335B1 (en) * 1998-06-15 2002-07-16 Dana Farber Cancer Institute, Inc. Combination of radiotherapy and anti-angiogenic factors
DK1140198T3 (da) 1999-01-13 2008-03-10 Alchemia Oncology Pty Ltd Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
JP2004505890A (ja) * 2000-04-04 2004-02-26 ノバルティス　アクチエンゲゼルシャフト 抗新生物剤に耐性の細胞を処置する方法
CA2410371C (en) * 2000-06-22 2015-11-17 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
CA2513143A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Also Published As

Publication number Publication date
EP2434282A2 (en) 2012-03-28
US20120095277A1 (en) 2012-04-19
US20040229843A1 (en) 2004-11-18
JP2005532373A (ja) 2005-10-27
AU2003280471A1 (en) 2004-01-19
WO2004003545A1 (en) 2004-01-08
US8093217B2 (en) 2012-01-10
WO2004003545A9 (en) 2004-04-15
EP2434282A3 (en) 2012-08-22
AU2003280471B2 (en) 2009-04-23
EP1532434A4 (en) 2009-05-27
EP1532434A1 (en) 2005-05-25
JP2010116410A (ja) 2010-05-27
CA2513143A1 (en) 2004-01-08
US8648047B2 (en) 2014-02-11

Similar Documents

Publication Publication Date Title
JP2010116410A (ja) ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物
KR100609646B1 (ko) Ｅｇｆ-ｒ 길항물질의 투여에 의한 기도 점액생산의 방지
US8183225B2 (en) Inhibition of bone resorption using medical implants containing adenosine receptor antagonists
Vaisitti et al. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor
Pan et al. Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases
Zhu et al. Sonic hedgehog promotes synovial inflammation and articular damage through p38 mitogen-activated protein kinase signaling in experimental arthritis
US9381245B2 (en) Methods for inhibiting osteolysis
WO2016100431A1 (en) Methods for treating inflammatory arthritis
WO2007117432A2 (en) Methods and compositions for modulating angiogenesis and tumor growth
Ao et al. Targeting GFPT2 to reinvigorate immunotherapy in EGFR-mutated NSCLC
CN119064582B (zh) RIPK1 O-GlcNAc糖基化抑制剂在制备增强肾细胞癌舒尼替尼敏感性药物中的应用
Kaur et al. Syndecans-the Signaling Controllers Possessing Prognostic Targetable Therapeutic Significance in Breast Cancer (BC)-for Innovative BC Therapy
Hampton et al. Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer
Tsumura et al. Conditional deletion of CD98hc inhibits osteoclast development
Tressler et al. A heparanase-inhibitory, bFGF-binding sulfated oligosaccharide that inhibits angiogenesis ex ovo has potent antitumor and antimetastatic activity in vivo
JP2017536353A (ja) がん治療のための医薬組成物及び薬物スクリーニング用バイオマーカー
Ritchie Heparanase drives the aggressive myeloma phenotype: Preclinical development of a heparanase inhibitor for the treatment of multiple myeloma
WO2022102722A1 (ja) 医薬組成物、細胞の製造方法、細胞、サーファクタントプロテインの製造方法、およびスクリーニング方法
Farrell et al. Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer
Langley et al. Phenotypic diversity of endothelial cells
Reynoso et al. Dietary downregulation of mutant p53 levels via glucose restriction
Bartova et al. Molecular Tumour Boards and Precision Medicine in Czech Oncology Centres
Oesterreich Targeting histone abnormality in triple negative breast cancer
KR20130121549A (ko) 혈관신생 억제제의 스크리닝 방법
MXPA01001755A (en) Preventing airway mucus production by administration of egf-r antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100125

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120529

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120622

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150629

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees